Delay from treatment start to full effect of immunotherapies for multiple sclerosis

In conclusion we have developed, and externally validated, a method to objectively quantify the duration of therapeutic lag on relapses and disability progres sion in different therapies in patients more than 3 years from multiple sclerosis onset. Objectively defined periods of expected therapeutic lag allows insights into the evaluation of treatment response in randomized clinical trials and may guide clinical decision-making in patients who experience e arly on-treatment disease activity. This method will subsequently be applied in studies that evaluate the effect of patient and disease characteristics on therapeutic lag.
Source: Brain - Category: Neurology Source Type: research